Enovis (NYSE:ENOV) Stock Rating Upgraded by Wall Street Zen

Enovis (NYSE:ENOV) was upgraded by stock analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday, Wall Street Zen reports.

A number of other equities research analysts have also recently weighed in on ENOV. BTIG Research lowered their price target on Enovis from $40.00 to $36.00 and set a “buy” rating on the stock in a report on Tuesday, September 1st. BMO Capital Markets set a $27.00 price objective on Enovis in a research report on Tuesday, September 1st. Needham & Company LLC dropped their price objective on shares of Enovis from $52.00 to $34.00 and set a “buy” rating on the stock in a report on Monday, October 12th. Wells Fargo & Company lowered their price target on shares of Enovis from $39.00 to $33.00 and set an “overweight” rating on the stock in a report on Wednesday, September 2nd. Finally, Evercore set a $32.00 price objective on shares of Enovis in a report on Monday, July 6th. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Enovis has an average rating of “Moderate Buy” and an average target price of $37.25.

Enovis Stock Performance

Shares of ENOV stock opened at $19.92 on Friday. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. The business’s 50 day simple moving average is $20.02 and its 200 day simple moving average is $23.08. The stock has a market capitalization of $1.15 billion, a PE ratio of -1.03 and a beta of 1.31. Enovis has a one year low of $16.70 and a one year high of $32.41.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The company had revenue of $582.78 million for the quarter, compared to analysts’ expectations of $581.84 million. During the same period in the previous year, the firm posted $0.79 EPS. Enovis’s revenue was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, research analysts forecast that Enovis will post 3.15 earnings per share for the current year.

Insider Buying and Selling at Enovis

In other Enovis news, insider Oliver Engert purchased 2,660 shares of the business’s stock in a transaction on Friday, September 4th. The shares were purchased at an average cost of $18.80 per share, with a total value of $50,008.00. Following the transaction, the insider directly owned 63,898 shares of the company’s stock, valued at $1,201,282.40. This represents a 4.34% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Damien Mcdonald bought 13,035 shares of Enovis stock in a transaction dated Friday, September 4th. The stock was purchased at an average price of $19.15 per share, with a total value of $249,620.25. Following the purchase, the chief executive officer owned 247,077 shares in the company, valued at approximately $4,731,524.55. This represents a 5.57% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 23,293 shares of company stock worth $449,599 in the last 90 days. 2.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Enovis

Several hedge funds have recently made changes to their positions in the business. IFP Advisors Inc raised its position in Enovis by 5,590.5% in the 2nd quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock worth $25,000 after purchasing an additional 1,174 shares during the last quarter. Allworth Financial LP purchased a new position in Enovis in the 2nd quarter worth $36,000. Integrated Wealth Concepts LLC purchased a new stake in Enovis during the 2nd quarter valued at about $39,000. Public Employees Retirement System of Ohio purchased a new stake in Enovis during the 2nd quarter valued at approximately $48,000. Finally, SBI Securities Co. Ltd. purchased a new position in shares of Enovis during the third quarter worth approximately $55,000. Institutional investors and hedge funds own 98.45% of the company’s stock.

About Enovis

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.